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Abstract
The overall survival for patients with primary glioblastoma is very poor. Glioblastoma contains a subpopulation of
glioma stem cells (GSC) that are responsible for tumour initiation, treatment resistance and recurrence. PPAR is
a transcription factor involved in the control of lipid, carbohydrate and amino acid metabolism. We have recently
shown that PPAR gene and protein expression is increased in glioblastoma and has independent clinical prognostic
significance in multivariate analyses. In this work, we report that PPAR is overexpressed in GSC compared to
foetal neural stem cells. To investigate the role of PPAR in GSC, we knocked down its expression using lentiviral
transduction with short hairpin RNA (shRNA). Transduced GSC were tagged with luciferase and stereotactically
xenografted into the striatum of NOD-SCID mice. Bioluminescent and magnetic resonance imaging showed that
knockdown (KD) of PPAR reduced the tumourigenicity of GSC in vivo. PPAR-expressing control GSC xenografts
formed invasive histological phenocopies of human glioblastoma, whereas PPAR KD GSC xenografts failed to
establish viable intracranial tumours. PPAR KD GSC showed significantly reduced proliferative capacity and
clonogenic potential in vitro with an increase in cellular senescence. In addition, PPAR KD resulted in significant
downregulation of the stem cell factors c-Myc, nestin and SOX2. This was accompanied by downregulation of
the PPAR-target genes and key regulators of fatty acid oxygenation ACOX1 and CPT1A, with no compensatory
increase in glycolytic flux. These data establish the aberrant overexpression of PPAR in GSC and demonstrate that
this expression functions as an important regulator of tumourigenesis, linking self-renewal and the malignant
phenotype in this aggressive cancer stem cell subpopulation. We conclude that targeting GSC PPAR expression
may be a therapeutically beneficial strategy with translational potential as an adjuvant treatment.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Gliomas form the most common group of primary cen-
tral nervous system (CNS) tumours, with an incidence
of 6.6 per 100 000 individuals/year [1]. A total of 50%
of adult gliomas are glioblastomas, which are associated
with poor clinical survival [2,3]. The median survival
is 15months in the setting of a clinical trial [4,5] and
12months using current treatment regimens [1,6,7].
The peroxisome proliferator-activated receptors
(PPARs) are ligand-activated transcription factors
with diverse metabolic functions [8]. PPARα activates
mitochondrial and peroxisomal fatty acid oxidation
and ketogenesis and inhibits glycolysis and fatty acid
synthesis [9–11]. Our previous work has shown that the
PPARA gene and its protein product are significantly
overexpressed in IDH-wild type primary glioblastomas
and that high PPARA expression functions as an inde-
pendent prognostic biomarker [12]. This finding has
been independently cross-validated in the Chinese
Glioma Genome Atlas [13].
PPARα agonists such as fenofibrate have clinical util-
ity in treating dyslipidaemia [14]. Fenofibrate reduces
glioma cell motility [15,16] and induces cell cycle arrest
and apoptosis in vitro [17,18]. Fenofibrate has also been
reported to exert anti-tumour effects by inducing keto-
genesis [19] and reducing glycolytic flux [20,21].
Stem-like cells have been identified in glioma in
vitro models [22,23] and glioma stem cells (GSC), with
the defining properties of self-renewal, multi-potency
and in vivo tumourigenicity being isolated from human
glioblastoma samples [24–26]. GSC are considered
responsible for tumour recurrence and treatment failure
[27,28]. Karyotypically normal, untransformed (foetal)
neural stem cells (NSC) share many features with
patient-derived GSC [29] and are ideal experimental
controls [30]. In order to improve our understanding of
GSC biology, the key regulatory pathways driving the
proliferation of this cancer stem cell population need to
be understood. Identification of factors that distinguish
NSC from transformed GSC may lead to new thera-
peutic agents designed to inhibit neoplastic growth with
minimal toxicity to the (adult) NSC compartment [31].
Several studies to date suggest that PPARα signalling
contributes to the proliferation of glioblastomas [12,32].
However, the role of PPARα expression in human GSC
populations is unknown. In this study, we tested the
hypothesis that PPARα expression contributes to the
malignant phenotype of GSC. We used RNA inter-
ference approaches to establish the role of PPARα in
maintaining the properties of GSC.
Methods
Cell culture
The human GSC (G144 and G26) and NSC (U5
and U3) cell lines (kind gifts from Dr Steve Pollard,
University of Edinburgh) were cultured as monolayers
in serum-free basal media [26,29]. HEK293T (human
embryonal kidney) cells (Sigma, St. Louis, MO, USA)
used for producing lentiviral particles were cultured in
DMEM (10% FBS and 1× non-essential amino acids).
All cell lines were cultured in 5% CO2 at 37
∘C.
Protein and RNA extraction
Total protein was extracted from cell lines using Mil-
liplex lysis buffer (Millipore, Burlington, MA, USA)
and quantified using a Qubit® Protein kit and fluorome-
ter (Life Technologies, Carlsbad, CA, USA). RNA was
extracted using an RNeasy® Plus Mini Kit (Qiagen,
Hilden, Germany) and the QIAcube® platform. RNA
was quantified using a NanoDrop1000 spectrophotome-
ter (ThermoFisher Scientific, Waltham, MA, USA).
Analysis of GSC and NSC accessioned microarray
data
Array data derived by Pollard et al (GSE15209) [26]
was accessed from https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi. Data analysis was performed using Partek
Genomics Suite v.6.16.0812 (Partek, St. Louis, MO,
USA) and normalised using GC-RMA. Differentially
expressed genes were analysed using an ANOVA. The
false discovery rate was set at an FDR-corrected p value
of <0.05 with a 1.5-fold expression change cut-off.
PPARA shRNA oligonucleotide design
Human (NCBI Gene ID: 5465) PPARA (22q13)
shRNA sequence primers were designed as previously
described [33] using the BLOCK-iT™ RNAi Designer
(https://rnaidesigner.thermofisher.com/rnaiexpress/).
Double-stranded shRNA constructs with an upstream
U6 promoter were produced using a pSilencer plasmid
as the PCR template. The forward primer sequence was
5′-CGACTCACTATAGGGCGAATTGGGT-3′, and the
reverse primer sequence contained the shRNA oligonu-
cleotide added to the 5′ tail (see supplementary material,
Table S1). Cloning of shRNA expression cassettes was
carried out as previously described [33,34], and the
resulting shRNA plasmids were validated using Sanger
sequencing (SourceBioscience; Nottingham, UK).
Generation of recombinant lentiviral particles
and transduction
U6.shRNA and scramble (SCR) cassettes were
cloned into an EGFP-expressing lentiviral backbone
(pRRL.sin.cppt.CMV.EGFP.WPRE). Viral particles
were produced and titred as described previously
[35]. Concentrated lentiviral particles were added to
G26 cells for 72 h (multiplicity of infection= 20).
Stable PPARα protein knockdown (KD) was estab-
lished, and a luciferase-expressing cassette (pCignal
Lenti-TRE-Reporter, CLS-PCR-1, Qiagen) was trans-
duced into the cells using polybrene (Sigma) at 8 μg/ml
before puromycin selection.
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In vitro cell proliferation studies
Cells were plated at 420 cells/mm2 and cultured for
72 h. The total cell number for each replicate for each
line was counted. Cells were re-plated at 420 cells/mm2,
and the experiment was repeated every 72 h for 15 days.
The fold increase in cell number over day 0 was
calculated using the mean value of each technical
replicate for each cell line at each independent time
point. Ki67 and caspase-3 fluorescence immunocy-
tochemistry was carried out as described previously
[36] using antibodies listed in supplementary material,
Supplementary materials and methods. CellTrace™
Violet proliferation studies were carried out according
to the manufacturer’s instructions (Thermofisher). The
proliferation control and experimental samples were
acquired on a Novocyte 3000 Flow Cytometer (Acea
Biosciences, San Diego, CA, USA). Data were anal-
ysed using ModFit LT v3.3 software (Verity Software
House, Topsham, ME, USA). Cell cycle analysis was
carried out on the platforms described above using
5 μM Draq5 nuclear stain (BioLegend, San Diego,
CA, USA) (15min incubation) and cells fixed in 4%
paraformaldehyde (PFA).
Colony-forming unit assay
Cells were plated at 16 cells/mm2 and cultured for
12 days. The cells were fixed (4% PFA) and then
stained with 1% crystal violet (Sigma). Calculation of
colony-forming unit (CFU) efficiency was determined
as described previously [37].
Senescence-associated β-galactosidase staining
Cells were plated at 520 cells/mm2 and cultured for
5 days. Cells were stained for 12 h using a Senescence
β-galactosidase Staining Kit (Cell Signalling Technolo-
gies, Danvers, MA, USA). Ten high-power fields (hpf)
were examined per well and positive (cytoplasmic and
nuclear blue) staining recorded as a percentage of total
live cells per hpf.
Intracranial xenografting procedure,
bioluminescent imagining and MRI
All animal-handling procedures and experiments were
performed in accordance with the UK Animal Scientific
Procedures Act 1986 and covered by UK Home Office
licenses (University of Leeds ethics committee project
license:PA5C8BDBF).
KD and SCR stably transduced cells were injected
into 7-week-old female NOD-SCID (NOD.CB17-
Prkdcscid/NcrCrl) mice (Charles River, Wilmington,
MA, USA); 30 000 cells were engrafted per animal (10
animals per cell line). Intracranial injection co-ordinates
were 1 mm rostral to bregma, 1.5 mm lateral (right) and
4 mm deep. Intracranial tumour growth was analysed
every 30 days using the Xenogen IVIS Spectrum in vivo
imaging system and 60mg/kg intraperitoneal D-luciferin
(Perkin Elmer, Waltham, MA, USA). MRI data were
acquired using a 7 T MRI System (AspectImaging,
Watford, UK). NIfTI format images were analysed
using MANGO (Mango Software, University of Texas,
TX, USA). Animals that had lost ≥20% of body weight
or showed persistent neurological signs were terminated
by pentobarbitone overdose followed by transcardial
4% PFA perfusion. The brain was removed and fixed in
4% PFA. The experiment ran for 25weeks.
Immunohistochemistry (IHC)
and immunofluorescence (IF)
Murine brain tissue was processed on a Leica Peloris
II histological platform (Leica, Wetzlar, Germany)
and H&E stained using a Leica Autostainer XL plat-
form (Leica). PPARα, Ki67 and EGFR IHC was carried
out using a Leica Bond III automated immunostainer
(Leica). IDH1, ATRX and GFAP IHC were carried out
using a Ventana BenchMark ULTRA platform (Roche,
Basel, Switzerland). Antigen retrieval techniques
and antibody concentrations are detailed in supplemen-
tary material, Supplementary materials and methods
and Table S4. EGFP immunofluorescence was carried
out as described previously [38].
Western blotting and RT-qPCR (reverse
transcription-quantitative PCR)
Western blotting was carried out as described previously
[36] (primary antibodies are listed in supplementary
material, Table S2). Extracted total RNA was reverse
transcribed to cDNA for quantitative real-time PCR
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA); qPCRwas
performed using a StepOne Plus Real-Time PCR system
and StepOne software v2.1 (Applied Biosystems) with
Taqman® Fast Gene Expression Mastermix (Applied
Biosystems), and Assay On Demand (AOD) products as
listed in supplementary material, Table S3.
Lactate and glucose assays
Cells were plated at 1000 cells/mm2 and cultured for
72–96 h. Adherent cells were counted, and the cul-
ture media was collected, centrifuged at 160× g and
the supernatant kept on ice. Lactate and glucose super-
natant concentrations were determined using a Cobas
8000 automated analyser (Roche) (lactate oxidase and
hexokinase methods, respectively).
Statistical analysis
The normality of data distributions were tested using
the Kolmogorov–Smirnov and D’Agostino and Pear-
son tests. A Wilcoxon matched pairs test or unpaired
t-test was used as appropriate. A Friedman test with
Dunn’s multiple comparison test was used for paired
non-parametric analysis of greater than two groups.
A two-way repeated-measures ANOVA was used to
compare in vitro cellular growth rates. All statisti-
cal tests were two-tailed. Differences with p < 0.05
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Figure 1. PPARα protein and PPARA gene expression are increased in GSC. (A) PPARα protein expression was examined in two NSC
lines and two GSC lines at three independent passages, n = 3. Protein expression values determined using densitometric analysis, with
PPARα-integrated area density values expressed relative to the loading control β-actin values. Expression values were calculated relative to
the grouped U3 control protein homogenates. Results of equivalent statistical significance were obtained when expression values were
calculated relative to the grouped U5 control protein homogenates. (B) High-power immunofluorescence microscopy showing mixed
nuclear/perinuclear and cytoplasmic expression of PPARα; ×630: oil immersion. Scale bar= 25 μm. (C) PPARA mRNA expression was
examined in NSC control and GSC in vitro models by RT-qPCR, normalised to the reference genes 18S and GAPDH (not shown). Expression
values were calculated relative to the grouped U3 control samples. Results of equivalent statistical significance were obtained when
expression values were calculated relative to the grouped U5 control samples. The geometric mean and 95% confidence interval are shown
on a logarithmic scale (to base2). n = 3 independent experiments, all samples analysed in triplicate. (D) PPARA expression in GSC (G166,
G174, G179, G144, GliNS) versus NSC versus normal adult brain tissue. In the box plots, the upper and lower ‘hinges’ correspond to the
25th and 75th percentiles, respectively. The upper/lower whisker extends to the highest/lowest value that is within 1.5× interquartile range
(IQR). Data beyond the end of the whiskers are outliers. Normalised and log-transformed mRNA gene-level summaries are shown. The test
statistic was a Friedman test with Dunn’s multiple comparison test (A and C) or a one-way ANOVA (D). Error bars show SEM. *p < 0.05, **
p < 0.01; ***p < 0.001; ns, non-significant; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 18S, 18 S ribosomal RNA.
were considered statistically significant. Data are rep-
resented as mean±SEM (geometric mean± 95% CI
for RT-qPCR data). Statistical tests were performed
using GraphPad Prism v5 (GraphPad Inc., San Diego,
CA, USA).
Results
PPARα protein and PPARA mRNA levels were
greater in GSC
PPARα protein expression was examined in three inde-
pendent passages of the U3 and U5 NSC lines and G144
and G26 GSC lines. There was a significant increase
in PPARα protein level in the G26 cell line compared
to both U3 (p = 0.032) and U5 cell lines (p = 0.048)
(Figure 1A). Immunofluorescence microscopy showed
a mixed nuclear/perinuclear and cytoplasmic expression
of PPARα in the GSC (Figure 1B). RT-qPCR was per-
formed for the U3, U5, G144 and G26 cell lines: there
was a significant increase in PPARAmRNA levels in the
G26 cell line compared to the U3 cell line (p = 0.039)
and the U5 cell line (p = 0.049) when normalised to
GAPDH or 18S expression (Figure 1C).
PPARA gene expression was increased in whole
transcriptome analysis of GSC versus NSC
Whole transcriptome expression profile data (accession
number GSE15209) were analysed. Using a 1.5-fold
change cut-off value (FDR threshold of 0.05), analysis
of PPARA expression showed that this transcript was
significantly increased in GSC compared to NSC and
normal adult brain tissue (p = 0.006, p = 0.001, respec-
tively) (Figure 1D). Increased expression of PPARAwas
noted to be within the second quintile of all overex-
pressed transcripts within the GSC versus NSC compar-
ison (p = 0.006, 1.65-fold change).
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PPARα KD inhibited GSC proliferation
and clonogenicity in vitro
To investigate the role of PPARα expression in GSC,
we generated a stable PPARα KD GSC cell line from
the G26 parent line. A control scrambled (SCR) shRNA
lentiviral construct was utilised. shRNA-mediated KD
of PPARα was confirmed by western blotting 60 days
after lentiviral transduction (see supplementary mate-
rial, Figure S1). The addition of a luciferase cassette had
no effect on shRNA PPARα KD efficiency.
PPARα KD lead to a significant decrease in the
PPARα KD cell population expansion compared to the
SCR shRNA cell population (p = 0.021) (population
doubling time: 2.3 days versus 1.3 days for KD shRNA
and SCR shRNA, respectively) (Figure 2A). There was
a significant decrease in Ki67 nuclear positivity between
SCR shRNA- versus PPARα KD shRNA-transduced
cells (30.0% versus 15.1%) (p = 0.003) (Figure 2B).
A CellTrace Violet (CTV) cell proliferation assay was
used to monitor cell divisions (generations) in PPARα
KD shRNA- and SCR shRNA-transduced cells. In
keeping with the population doubling studies described
above, PPARα KD shRNA-transduced cells showed a
significant reduction in proliferation index compared to
SCR shRNA-transduced cells (p = 0.002) (Figure 2C).
In addition, the proportion of cells in the G1 phase of
the cell cycle was shown to be significantly increased in
the PPARα KD shRNA cell line compared to the SCR
shRNA cell line (p = 0.034) (Figure 2D). We also stud-
ied the effect of stable PPARαKD on clonogenicity. The
mean number of colonies formed by PPARα KD cells
was reduced by 53.5% relative to SCR shRNA cells
(p = 0.029) (Figure 2E). There was also a significant
increase in β-galactosidase (pH 6.0) positivity, a known
characteristic of senescent cells, between SCR shRNA-
versus PPARα KD shRNA-transduced cells (6.8%
versus 16.4%, p = 0.008) (Figure 2F). In conjunction
with this, PPARα KD shRNA-transduced cells were
found to have aberrant cytonuclear features compared
to SCR shRNA controls: the cells were notably larger
and flattened with a frequent loss of the spindle mor-
phology. Increased intracytoplasmic vacuolation and
multi-nucleation was also noted with strong perinuclear
β-galactosidase positivity (Figure 2F).
PPARα kD suppressed the tumourigenicity of GSC
orthotopic xenografts
SCR and PPARα KD shRNA-transduced G26 cells
were stereotactically implanted in a NOD SCID murine
model, and the effect on tumour initiation and progres-
sion was monitored. Fourteen days after xenografting,
all animals showed detectable bioluminescence (BLI)
signal. There was significantly less BLI signal in the
PPARα KD group compared to the SCR shRNA
control group at each time point during the course
of the experiment (Figure 3A). Remaining animals
(n = 8) were terminated after 25weeks (Figure 3B).
T2-weighted MRI was performed 2 h antemortem. The
SCR shRNA group showed evidence of right-sided
hemispheric T2-hyperintense lesions with mass effect
(Figure 3C). The PPARα KD experimental group
showed no MRI signs of intracranial abnormality
(Figure 3C). Twenty-five weeks after the xenograft
procedure, low power histological examination of
the brains from the control SCR shRNA xenograft
arm (n = 4) demonstrated extensive tumour formation
(Figure 3D).
All SCR shRNA xenograft experiments produced
tumour masses with histological (H&E) evidence of
non-circumscribed cellular tumours consisting of pleo-
morphic cells (Figure 3D) with frequent atypical mitotic
figures. Ki67 IHC showed variable nuclear positivity
across the tumour field (focal areas of >50% Ki67 posi-
tivity) and diffuse infiltration by Ki67-positive cells into
the adjacent host parenchyma (Figure 4A). PPARα IHC
showed extensive cytoplasmic and nuclear positivity
(Figure 4A). IHC performed on SCR shRNA xenografts
showed the tumour cells to be negative for the expres-
sion of the IDH1R132H-mutated protein product with
strong nuclear ATRX expression and GFAP and EGFR
immunopositivity (Figure 4B). EGFP expression exam-
ined by immunofluorescence recapitulated the malig-
nant infiltration into the host parenchyma described
above (Figure 4B). In contrast, the KD shRNAxenograft
arm of the experiment showed no histological evidence
of tumour formation (Figure 4C). Immunofluorescence
microscopy of brains from the KD shRNA xenograft
arm of the experiment demonstrated single cells with
EGFP immunopositivity (negative for human-specific
Ki67; Figure 4C). These cells were scattered at the
lateral aspect of the right anterior commissure, an area
just medial to the stereotactic injection site (Figure 4D).
No EGFP-positive cells were observed in any other
brain regions.
PPARα shRNA KD altered the protein and gene
expression of stem cell and mitogenic markers
Transduced G26 cells were examined by western blot-
ting to assess any effects on the protein expression
of key signalling mediators that occurred concomitantly
with the stable KD of PPARα. The expression of c-Myc
(p = 0.029) and Cyclin D1 (p = 0.035) proteins were
significantly reduced (Figure 5A). The stem cell mark-
ers nestin and SOX2 showed similarly decreased
protein expression (p = 0.037, p = 0.023, respectively)
(Figure 5A). The expression of the astrocytic differ-
entiation marker GFAP was increased (p = 0.022)
(Figure 5A). The PPARα transcription target EGFR
showed a reduced protein expression (Figure 5A).
Across multiple independent passages, no PARP cleav-
age was observed by western blot in the KD shRNA
cell lines, establishing that the reduced proliferation
rates described were not due to increased apoptosis.
Indeed, no increase in active caspase 3 was observed
by immunofluorescence in the KD shRNA cell line
(Figure 5B).
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Figure 2. PPARα KD inhibited GSC proliferation and clonogenicity in vitro. (A) There was a significant fold decrease in proliferation in the
PPARα KD GSC population compared to the SCR shRNA GSC population (population doubling time: 2.3 days versus 1.3 days, KD shRNA and
SCR shRNA, respectively). The test statistic was a two-way repeated-measures ANOVA and Bonferroni post hoc test. Data were analysed
using nonlinear regression with y = 0 (constrained). Increase (fold-change) in cell number shown on a logarithmic scale (to base2). (B)
There was a significant reduction of the Ki67 index in the PPARα KD GSC population compared to the SCR shRNA GSC population. The
proportion of Ki67 nuclear positivity was quantified as the proportion of total nuclei per high-power field (×200). Ten high-power fields were
examined per slide/technical replicate. Nuclei labelled with DAPI nuclear dye. n = 3, three technical replicates per independent experiment.
Representative Ki67 IF images shown. Scale bar= 50 μm. (C) CTV cell proliferation assay; PPARα KD GSC showed a reduction in proliferation
index (sum of the cells in all generations divided by the computed number of original parent cells theoretically present at the start of
the experiment, where each daughter cell has half the CTV fluorescence intensity of its parental cell). Analysis was carried out using a
Novocyte 3000 Flow Cytometer with 405 nm excitation laser and 445/45 nm Band Pass (BP) filter. n = 3, three technical replicates per
independent experiment. (D) There was a significant increase in G1 phase cells with PPARα KD. Draq5 analysis was carried out using a
Novocyte 3000 Flow Cytometer with 640 nm excitation laser and 780/60 nm BP filter. n = 3, three technical replicates per independent
experiment. (E) There was a significant reduction in the number of colonies in the PPARα KD GSC population compared to the SCR shRNA
cell population. Representative images of clonogenic assays are shown. (F) There was a significant increase in senescence-associated
β-galactosidase staining in the PPARα KD GSC population compared to the SCR shRNA cell population. Representative high-power images
of β-galactosidase staining are shown. n = 3, three technical replicates per independent passage. The test statistic was a Wilcoxon matched
pair test, two-tailed p value (B–F). Error bars show SEM. SCR, scrambled control; *p < 0.05, **p < 0.01.
Using RT-qPCR we found a significant reduction in
PPARA mRNA levels in the KD shRNA cell lines com-
pared to the SCR shRNA lines when normalised to
GAPDH (p = 0.022) and 18S expression (p = 0.001)
(Figure 5C). In keeping with the western blotting analy-
sis of protein, there was a significant reduction in the
expression of the stem cell markers NES and SOX2
in the KD shRNA cell lines compared to the SCR
shRNA lines when normalised to GAPDH (p = 0.001,
p = 0.002, respectively) and 18S expression (p = 0.01,
p = 0.002, respectively) (Figure 5C). There was also a
reduction in cMYC expression in the KD shRNA cell
lines when normalised to GAPDH and 18S expression
(p = 0.025, p = 0.027, respectively) (Figure 5C).
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Figure 3. PPARα KD inhibited GSC tumourigenicity in vivo. (A) SCR- and KD shRNA-transduced G26 cells were stereotactically implanted
in a NOD-SCID orthotopic murine model and the effect on tumour initiation and progression monitored. At 11weeks after the xenografting
procedure, all animals showed detectable BLI signal (p/s/cm2/sr). There was a significant decrease in BLI signal in the PPARα KD group
compared to the SCR shRNA control group. (B) All remaining animals (n = 8) were terminated after 25weeks. (C) T2-weighted MRI was
performed 2 h antemortem. The SCR shRNA group showed evidence of extensive right-sided hemispheric T2-hyperintense masses (axial).
The PPARα KD experimental group showed no radiological evidence of any intracranial abnormality (red box denotes stereotactic injection
site). (D) A total of 25weeks after the xenograft procedure, low and power histological examination of the brains from the control SCR
shRNA xenograft arm demonstrated tumour formation. All SCR shRNA xenograft experiments produced tumour masses with histological
(H&E) evidence of high cellularity with pleomorphic tumour cells. Representative images shown (coronal sections). Red boxes denote areas
shown at greater magnification. Scale bar= 1000 μm (i, iii); scale bar= 100 μm (ii); scale bar= 50 μm (iv). R, right hand side.
The PPARα-regulated fatty acid oxidation enzymes
ACOX1 and CPT1a were also examined by RT-qPCR.
A reduction in ACOX1 was seen when normalised to
18S expression (p = 0.027) (Figure 5C). There was a
reduction in the expression of CPT1A in the KD shRNA
cell lines compared to the SCR shRNA lines when
normalised toGAPDH (p = 0.0002) and 18S expression
(p = 0.004) (Figure 5C).
PPARα shRNA KD had no significant effect
on lactate production or glucose consumption in
vitro
Biochemical analysis was performed on media har-
vested from shRNA-transduced cells after 72 and 96 h
expansion in vitro. There was no difference in lactate
production between SCR shRNA cells and KD shRNA
cells after 72 or 96 h (p = 0.103; p = 0.092, respec-
tively) (Figure 5D). There was no significant differ-
ence in relative glucose concentration in the harvested
media between SCR shRNA cells and KD shRNA cells
after 72 or 96 h (p = 0.172, p = 0.087, respectively)
(Figure 5E).
Discussion
A key area of investigation in the search for more
effective treatments for glioblastoma is the molec-
ular manipulation of self-renewal and proliferation
pathways in GSC [39]. Direct targeting of GSC may
also improve the efficacy of conventional chemo-
and radiotherapy [40]. Transcription factors overex-
pressed in GSC could provide effective treatment
targets for novel therapeutic agents. In this study, GSC
were shown to express increased levels of PPARα
protein and PPARA transcript when compared to
NSC controls. NSC share key functional and genetic
similarities to GSC and are considered an ideal exper-
imental control in this setting [30]. The analyses of
PPARA expression in accessioned microarray data
cross-validated the findings derived from our in vitro
models. Indeed, the increased expression of PPARAwas
suggested in this work to be a significant finding shared
across multiple GSC cell lines. The molecular mech-
anisms underlying this increased expression remain
to be elucidated and are an important area of future
investigation.
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Figure 4. SCR shRNA xenografts: IHC and IF performed on harvestedmouse brains 25weeks after GSC implantation. (A) (i–iv) Representative
Ki67 IHC. (v, vi) Representative PPARα IHC. Scale bar= 1000 μm (i, ii); scale bar= 100 μm (iii–vi). (B) SCR shRNA xenograft: IHC and IF (EGFP)
performed on harvested mouse brain 25weeks after GSC implantation. Scale bar= 1000 μm (i–v); scale bar= 50 μm (vi). (C) Representative
H&E image of a coronal section and Ki67 IHC performed on a consecutive tissue section. Scale bar= 1000 μm (i, ii); 100 μm (iii, iv). (D)
Immunofluorescence microscopy detection of EGFP-positive cells. The inset in the immunofluorescent image denotes the hatched area
×400. Scale bar= 100 μm. R, right hand side. Red boxes denote areas shown at greater magnification (C and D).
We selected the well-validated IDH1-wildtype,
non-CpG island methylated G26 GSC line as a target
for our lentiviral transduction work to best recapitu-
late a primary glioblastoma GSC subpopulation [41].
Stable KD of PPARα protein expression resulted in
a significantly reduced in vitro growth rate. This was
confirmed using flow cytometric generational tracing,
which showed a decrease in the number of cell divisions
per unit time. PPARα KD additionally reduced the
clonogenicity of the GSC line. These results indicate
that PPARα is required for, or plays a key role in, the
maintenance of GSC proliferative capacity.
Examination of the PPARα KD shRNA-transduced
cells demonstrated a significant increase in
senescence-associated β-gal staining in vitro, indi-
cating the induction of senescence. Cellular senescence
implies a stable and long-term loss of proliferation
capacity with no loss of cellular viability or metabolic
activity [42–44]. Long-term exit from the cell cycle
has been suggested as a key marker of cellular senes-
cence [42], and PPARα KD resulted in evidence of cell
cycle arrest. Morphological changes consistent with
a senescent phenotype were also observed [42]. It is
noteworthy that this indicates that molecular senescence
mechanisms may remain latently functional even in
aggressive GSC populations.
A defining functional characteristic of GSC is
their ability to initiate and propagate histological
phenocopies of human glioblastoma when xenografted
intra-cranially in immunocompromised animals [45,46].
We used orthotopic xenotransplantation to investigate
the functional requirement of PPARα to maintain the
tumourigenic potential of human GSC. The xenograft
brains in the control SCR shRNA experimental arm
showed the key histological features of a human
glioblastoma. Immunophenotyping demonstrated IDH1
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 247: 422–434
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Figure 5. Legend on next page
mutation-negative tumour cells with strong nuclear
ATRX expression [47,48] and EGFR overexpression
[49,50], confirming an expression profile consis-
tent with IDH-wildtype primary glioblastoma [51].
Conversely, radiological and histological examina-
tion showed that PPARα KD xenografts did not
form significant tumour masses in vivo, indicating
that GSC lacking PPARα expression have markedly
reduced tumour-initiating capacity. Nevertheless,
the immunofluorescence examination of PPARα KD
GSC-engrafted brains demonstrated EGFP-positive
cells at the injection sites, confirming successful cell
engraftment. We concluded that these EGFP-positive
cells have a significantly reduced proliferation rate but
remain viable over an extended time course in vivo,
in keeping with the hallmarks of senescent cells. Such
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scattered EGFP-positive cells may provide sufficient
signal for BLI detection in the absence of an observed
tumour mass, as has been previously reported [52].
It has been shown that both PPARα pharmacologi-
cal antagonism and siRNA-mediated PPARαKD reduce
the expression of c-Myc, cyclin D1 and CDK4 in renal
cell carcinoma (RCC) in vitro models [53]. The PPARα
agonist Wy-14643 has also been shown to decrease the
expression of the let-7C miRNA in wild-type mice, with
no similar repression seen in PPARα-null animals [54].
let-7C miRNA targets and represses c-Myc expression
[54]. c-Myc plays a role in the initiation and prolif-
eration of glial brain tumours, and there is evidence
of deregulation of the c-Myc pathway in glioblastoma
[55–57]. The full transcriptional functions of c-Myc
remain to be elucidated [58], but the induction of cyclin
D1 [59] and the repression of p21WAF1/CIP1 expression
have been previously reported [60,61]. We investigated
a putative PPARα/c-Myc interaction in our PPARα KD
in vitro model: c-Myc protein expression was found to
be decreased in shRNA-mediated PPARαKDGSC. This
was accompanied by a significant decrease in cyclin D1
expression and a concomitant G1 phase cell cycle arrest.
PPARα has also been reported to play a role
in EGFR phosphorylation and activation [62,63].
PPARα-LXRα/RXRα heterodimers positively regulate
EGFR promotor activity, and a putative PPARα DNA
response element has been described upstream of the
EGFR promoter [63]. We have previously reported that
EGFR mRNA expression significantly correlates with
high PPARA mRNA expression in the TCGA primary
glioblastoma dataset [12]. In keeping with these find-
ings in surgical tumour specimens, PPARα KD in GSC
was found to significantly reduce the protein expression
of EGFR in vitro. EGFR activation and subsequent
receptor dimerisation promote cellular proliferation
via activation of the MAPK and PI3K-Akt pathways
[64], and this reduction of EGFR expression may be an
additional factor in the decreased expression of c-Myc,
which is an immediate early-response gene downstream
of many ligand–membrane receptor complexes [58].
PPARα KD also resulted in reduced expression
of nestin and SOX2 proteins with an increase in
GFAP protein expression. GFAP is a commonly used
astrocyte maturation marker [65–67]. GSC popu-
lations are known to upregulate GFAP along with
other astrocyte differentiation markers (AQP4 and
ALDH1A1) following the induction of a differenti-
ated and cell cycle-arrested state [26,68]. The altered
expression of this differentiation marker was there-
fore in keeping with a reduction in GSC proliferative
capacity and a senescent (post-mitotic) state. Whether
this PPARα KD-driven cellular state is reversible or
represents terminal differentiation warrants further
investigation (Figure 6) [69].
PPARα drives the transcription of key fatty
acid oxidation (FAO) enzymes, including carnitine
palmitoyltransferase 1 alpha (CPT1α; CPT1A) and
acyl-coenzyme A oxidase 1 (ACOX1) [8]. Both murine
sub-ventricular zone NSC and human GSC have been
reported as being dependent on FAO [70,71]. In this
study, PPARα KD reduced the gene expression of
CPT1A and ACOX1, with a concomitant reduction in
proliferation and clonogenic potential. PPARα antag-
onism in RCC models decreases FAO and enhances
glycolysis [53]. We assayed in vitro lactate and glucose
concentrations and showed that a compensatory increase
in glycolysis (pyruvate to lactate conversion; the
Warburg effect [72]) did not occur in GSC. This may
be due to the reduction in c-Myc expression, which
has been associated with decreased glycolytic rates
[73–75]. In addition, we propose that FAO-dependent
GSC have only a small requirement for glucose oxi-
dation [70,76], and PPARα KD, through effects on
FAO enzyme expression, may deplete GSC popula-
tions of their prime FAO bioenergetic source with
no compensatory glycolytic flux, resulting in the
anti-proliferative phenotype described. Interestingly,
the unique metabolic requirements of GSC compared
to the aberrantly differentiated cells of the tumour mass
[40] may explain the paradox of increased PPARA
expression in mediating prolonged clinical survival
[12] versus KD of PPARα in GSC inhibiting tumour
growth. We hypothesise that high PPARA exerts an
inhibitory effect on glioblastoma glycolysis [77], an
effect not seen in the GSC population. The differing
Figure 5. PPARα KD reduced the protein and gene expression of stemness markers in vitro with no effect on glycolytic flux. (A) Protein
expression was examined at three independent passages, n = 3. Protein expression values determined using densitometric analysis, with
protein-integrated area density values expressed relative to the loading control β-actin values. Expression values were calculated relative
to the PPARα expression values. Representative western blot shown. (B) There was no significant reduction of the active caspase 3 index
in the PPARα KD GSC population compared to the SCR shRNA GSC population. The proportion of active caspase 3 cellular positivity was
quantified as a proportion of total nuclei per high-power field (×200). Ten high-power fields were examined per slide/technical replicate.
Nuclei were labelled with DAPI nuclear dye. n = 3, three technical replicates per independent experiment. Representative active caspase 3 IF
images shown. (C) mRNA expression was examined in the PPARα KD GSC population compared to the WT and SCR shRNA GSC population by
RT-qPCR, normalised to the reference genes 18S and GAPDH. Relative gene expression (expressed as a fold-difference compared to control
samples) was calculated using the 2−ΔΔCt method, and expression values were calculated relative to the WT control samples. The geometric
mean and 95% confidence interval are shown on a logarithmic scale (to base2). n = 3 independent experiments; all samples analysed
in triplicate. (D) Culture growth media lactate and glucose concentration was examined in three independent passages. Lactate/glucose
concentrations were normalised to cell number at the time of media harvest. The concentration of analyte in blank control wells was
subtracted from each assay output, which was then normalised to the total cell number in each well. The test statistic was a Wilcoxon
matched pair test, two-tailed P value (A) or a Friedman test with Dunn’s multiple comparison test (C–E). Error bars show SEM. WT, wild
type; SCR, scrambled; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 18S, 18 S ribosomal RNA; *p < 0.05, **p < 0.01, ***p < 0.001;
ns, non-significant.
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Figure 6. Schematic model of the effects of PPARα KD in a GSC in vitro model. PPARα KD exerts an anti-proliferative effect on GSC via an
altered stemness phenotype, increased rates of cellular senescence and putative changes in the metabolic flux of the GSC population. It is
hypothesised that this may be attributed to downstream changes in key molecular mediators of malignant transformation such as c-Myc,
EGFR and cyclin D1.
roles of molecular mediators of malignancy in disparate
GSC and tumour mass cell populations is a key area
for future investigation and has crucial implications
when designing adjuvant treatment strategies to inhibit
tumour recurrence.
In summary, our study establishes the expression of
PPARα in GSC. The stable KD of PPARα in GSC com-
pletely abolished intracranial tumour formation. This
was associated with the induction of cellular senescence
in vitro, driven by the reduced expression of mitogenic
and stemness factors. These data provide evidence of the
role of PPARα in GSC as an important molecular regula-
tor, linking proliferation and self-renewal with a critical
role in maintaining the malignant phenotype. Targeting
PPARα in GSC populations may therefore have transla-
tional potential as a novel adjuvant therapeutic approach
to abrogate the contribution of GSC to the poor overall
clinical survival for glioblastoma patients.
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